Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA.
J Biol Chem. 2010 Mar 19;285(12):8615-20. doi: 10.1074/jbc.M109.074708. Epub 2010 Jan 18.
Enhancement of gamma-aminobutyric acid type A receptor (GABA(A)R)-mediated inhibition is a property of most general anesthetics and a candidate for a molecular mechanism of anesthesia. Intravenous anesthetics, including etomidate, propofol, barbiturates, and neuroactive steroids, as well as volatile anesthetics and long-chain alcohols, all enhance GABA(A)R function at anesthetic concentrations. The implied existence of a receptor site for anesthetics on the GABA(A)R protein was supported by identification, using photoaffinity labeling, of a binding site for etomidate within the GABA(A)R transmembrane domain at the beta-alpha subunit interface; the etomidate analog [(3)H]azietomidate photolabeled in a pharmacologically specific manner two amino acids, alpha1Met-236 in the M1 helix and betaMet-286 in the M3 helix (Li, G. D., Chiara, D. C., Sawyer, G. W., Husain, S. S., Olsen, R. W., and Cohen, J. B. (2006) J. Neurosci. 26, 11599-11605). Here, we use [(3)H]azietomidate photolabeling of bovine brain GABA(A)Rs to determine whether other structural classes of anesthetics interact with the etomidate binding site. Photolabeling was inhibited by anesthetic concentrations of propofol, barbiturates, and the volatile agent isoflurane, at low millimolar concentrations, but not by octanol or ethanol. Inhibition by barbiturates, which was pharmacologically specific and stereospecific, and by propofol was only partial, consistent with allosteric interactions, whereas isoflurane inhibition was nearly complete, apparently competitive. Protein sequencing showed that propofol inhibited to the same extent the photolabeling of alpha1Met-236 and betaMet-286. These results indicate that several classes of general anesthetics modulate etomidate binding to the GABA(A)R: isoflurane binds directly to the site with millimolar affinity, whereas propofol and barbiturates inhibit binding but do not bind in a mutually exclusive manner with etomidate.
增强γ-氨基丁酸 A 型受体 (GABA(A)R) 介导的抑制作用是大多数全身麻醉药物的特性,也是麻醉分子机制的候选者。静脉内麻醉剂,包括依托咪酯、丙泊酚、巴比妥类药物和神经活性甾体,以及挥发性麻醉剂和长链醇,在麻醉浓度下均增强 GABA(A)R 功能。使用光亲和标记法,在 GABA(A)R 跨膜域的β-α亚基界面内鉴定出依托咪酯的结合位点,从而支持了麻醉剂在 GABA(A)R 蛋白上存在受体位点的假设;依托咪酯类似物 [(3)H]azietomidate 以药理学特异性方式标记了两个氨基酸,M1 螺旋中的 alpha1Met-236 和 M3 螺旋中的 betaMet-286(Li,G.D.,Chiara,D.C.,Sawyer,G.W.,Husain,S.S.,Olsen,R.W.,和 Cohen,J.B.(2006)J. Neurosci. 26,11599-11605)。在这里,我们使用 [(3)H]azietomidate 对牛脑 GABA(A)R 的光标记来确定其他结构类别的麻醉剂是否与依托咪酯结合位点相互作用。在低毫摩尔浓度下,麻醉浓度的丙泊酚、巴比妥类药物和挥发性麻醉剂异氟烷抑制光标记,但辛醇或乙醇则没有。巴比妥类药物的抑制作用具有药理学特异性和立体特异性,而丙泊酚的抑制作用则不完全,与变构相互作用一致,而异氟烷的抑制作用则几乎完全,显然是竞争性的。蛋白质测序表明,丙泊酚以相同的程度抑制 alpha1Met-236 和 betaMet-286 的光标记。这些结果表明,几类全身麻醉剂调节依托咪酯与 GABA(A)R 的结合:异氟烷以毫摩尔亲和力直接结合到该位点,而丙泊酚和巴比妥类药物抑制结合但不以相互排斥的方式与依托咪酯结合。